Scienture (NASDAQ:SCNX) Stock to Reverse Split on Monday, October 5th

Scienture Holdings, Inc. (NASDAQ:SCNX)’s stock is scheduled to reverse split on Monday, October 5th. The 1-25 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Sunday, October 4th.

Scienture Stock Performance

Shares of NASDAQ:SCNX traded down $0.08 during midday trading on Thursday, hitting $0.18. The company had a trading volume of 1,900,908 shares, compared to its average volume of 1,572,648. Scienture has a 12-month low of $0.18 and a 12-month high of $2.60. The company has a fifty day moving average of $0.37 and a two-hundred day moving average of $0.38. The company has a market cap of $7.27 million, a price-to-earnings ratio of -0.08 and a beta of 3.35. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.04 and a quick ratio of 2.97.

Scienture (NASDAQ:SCNX) last announced its earnings results on Thursday, August 13th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.02. The company had revenue of $0.34 million during the quarter, compared to the consensus estimate of $1.96 million.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Scienture in a research note on Monday, September 21st. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Scienture currently has an average rating of “Hold” and an average target price of $1.50.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Scienture stock. Susquehanna International Group LLP purchased a new position in Scienture Holdings, Inc. (NASDAQ:SCNX) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 235,117 shares of the company’s stock, valued at approximately $82,000. Susquehanna International Group LLP owned approximately 0.57% of Scienture as of its most recent filing with the Securities and Exchange Commission. 5.68% of the stock is currently owned by institutional investors.

Scienture Company Profile

Scienture Holdings, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for central nervous system and other underserved medical conditions. The company’s strategy centers on differentiated medicines designed to address unmet patient and caregiver needs, including alternative formulations and delivery options.

Scienture’s lead product is ONYDA XR (clonidine hydrochloride) extended-release oral suspension, a non-stimulant prescription treatment for attention-deficit/hyperactivity disorder (ADHD).